The BERGAMO multicenter phase 2 trial (NCT03824080) evaluated the safety and efficacy of the oral, selective, small molecule AXL inhibitor bemcentinib (BEM) in patients with HR-MDS or AML not eligible for IC or alloSCT, refractory or relapsing after at least six cycles of azacitidine (AZA) or four cycles of decitabine (DAC). This evidence concerns the gene AXL and myelodysplastic syndrome.